SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-23-000856
Filing Date
2023-08-11
Accepted
2023-08-11 16:23:49
Documents
2
Group Members
ORBIMED ADVISORS III LTDORBIMED ASIA GP III, L.P.ORBIMED CAPITAL LLCORBIMED GENESIS GP LLCORBIMED NEW HORIZONS GP LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 ss2381377_sc13da.htm SC 13D/A 195723
2 JOINT FILING AGREEMENT ss2381377_ex9901.htm EX-99.1 9893
  Complete submission text file 0000947871-23-000856.txt   207349
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address BUILDING 3, 418 GUILIN ROAD XUHUI DISTRICT SHANGHAI F4 200030
Business Address BUILDING 3, 418 GUILIN ROAD XUHUI DISTRICT SHANGHAI F4 200030 00862164031522
Gracell Biotechnologies Inc. (Subject) CIK: 0001826492 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91967 | Film No.: 231164472
SIC: 2834 Pharmaceutical Preparations